Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 21
Filter
1.
J Cyst Fibros ; 2024 Apr 23.
Article in English | MEDLINE | ID: mdl-38658252

ABSTRACT

BACKGROUND: Newborn bloodspot screening (NBS) for cystic fibrosis (CF) is important for early diagnosis and treatment. However, screening can lead to false-positive results leading to unnecessary follow-up tests and distress. This study evaluated the 11-year performance of the Swiss CF-NBS programme, estimated optimal cut-offs for immunoreactive trypsinogen (IRT), and examined how simulated algorithms would change performance. METHODS: The Swiss CF-NBS is based on an IRT-DNA algorithm with a second IRT (IRT-2) as safety net. We analysed data from 2011 to 2021, covering 959,006 IRT-1 analyses and 282 children with CF. We studied performance based on European Cystic Fibrosis Society (ECFS) standards including sensitivity, specificity, positive predictive value (PPV), false negative rate, and second heel-prick tests; identified optimal IRT cut-offs using receiver operating characteristics (ROC) curves; and calculated performance for simulated algorithms with different cut-offs for IRT-1, IRT-2, and safety net. RESULTS: The Swiss CF-NBS showed excellent sensitivity (96 %, 10 false negative cases) but moderate PPV (25 %). Optimal IRT-1 and IRT-2 cut-offs were identified at 2.7 (>99th percentile) and 5.9 (>99.8th percentile) z-scores, respectively. Analysis of simulated algorithms showed that removing the safety net from the current algorithm could increase PPV to 30 % and eliminate >200 second heel-prick tests per year, while keeping sensitivity at 95 %. CONCLUSION: The Swiss CF-NBS program performed well over 11 years but did not achieve the ECFS standards for PPV (≥30 %). Modifying or removing the safety net could improve PPV and reduce unnecessary follow-up tests while maintaining the ECFS standards for sensitivity.

2.
Pneumologie ; 74(8): 515-544, 2020 Aug.
Article in German | MEDLINE | ID: mdl-32823360

ABSTRACT

The present guideline aims to improve the evidence-based management of children and adolescents with pediatric community-acquired pneumonia (pCAP). Despite a prevalence of approx. 300 cases per 100 000 children per year in Central Europe, mortality is very low. Prevention includes infection control measures and comprehensive immunization. The diagnosis can and should be established clinically by history, physical examination and pulse oximetry, with fever and tachypnea as cardinal features. Additional signs or symptoms such as severely compromised general condition, poor feeding, dehydration, altered consciousness or seizures discriminate subjects with severe pCAP from those with non-severe pCAP. Within an age-dependent spectrum of infectious agents, bacterial etiology cannot be reliably differentiated from viral or mixed infections by currently available biomarkers. Most children and adolescents with non-severe pCAP and oxygen saturation > 92 % can be managed as outpatients without laboratory/microbiology workup or imaging. Anti-infective agents are not generally indicated and can be safely withheld especially in children of young age, with wheeze or other indices suggesting a viral origin. For calculated antibiotic therapy, aminopenicillins are the preferred drug class with comparable efficacy of oral (amoxicillin) and intravenous administration (ampicillin). Follow-up evaluation after 48 - 72 hours is mandatory for the assessment of clinical course, treatment success and potential complications such as parapneumonic pleural effusion or empyema, which may necessitate alternative or add-on therapy.


Subject(s)
Anti-Bacterial Agents/therapeutic use , Community-Acquired Infections/drug therapy , Pneumonia/drug therapy , Practice Guidelines as Topic , Pulmonary Medicine/standards , Adolescent , Anti-Bacterial Agents/administration & dosage , Child , Community-Acquired Infections/diagnosis , Community-Acquired Infections/virology , Europe , Germany , Humans , Infant , Pneumonia/diagnosis , Pneumonia/virology , Societies, Medical
4.
Mucosal Immunol ; 6(4): 797-806, 2013 Jul.
Article in English | MEDLINE | ID: mdl-23212197

ABSTRACT

Deficient type I interferon-ß and type III interferon-λ induction by rhinoviruses has previously been reported in mild/moderate atopic asthmatic adults. No studies have yet investigated if this occurs in severe therapy resistant asthma (STRA). Here, we show that compared with non-allergic healthy control children, bronchial epithelial cells cultured ex vivo from severe therapy resistant atopic asthmatic children have profoundly impaired interferon-ß and interferon-λ mRNA and protein in response to rhinovirus (RV) and polyIC stimulation. Severe treatment resistant asthmatics also exhibited increased virus load, which negatively correlated with interferon mRNA levels. Furthermore, uninfected cells from severe therapy resistant asthmatic children showed lower levels of Toll-like receptor-3 mRNA and reduced retinoic acid inducible gene and melanoma differentiation-associated gene 5 mRNA after RV stimulation. These data expand on the original work, suggesting that the innate anti-viral response to RVs is impaired in asthmatic tissues and demonstrate that this is a feature of STRA.


Subject(s)
Asthma/genetics , Asthma/immunology , Hypersensitivity, Immediate/genetics , Hypersensitivity, Immediate/immunology , Immunity, Innate/genetics , Interferons/genetics , Adolescent , Asthma/metabolism , Child , Child, Preschool , DEAD Box Protein 58 , DEAD-box RNA Helicases/genetics , DEAD-box RNA Helicases/metabolism , Female , Gene Expression Regulation , Humans , Hypersensitivity, Immediate/metabolism , Immunoglobulin E/immunology , Interferon-Induced Helicase, IFIH1 , Interferon-beta/genetics , Interferon-gamma/genetics , Interleukin-8/biosynthesis , Lung/immunology , Lung/metabolism , Lung/virology , Male , Picornaviridae Infections/genetics , Picornaviridae Infections/immunology , Poly I-C/administration & dosage , Poly I-C/immunology , RNA, Messenger/genetics , Receptors, Immunologic , Respiratory Mucosa/drug effects , Respiratory Mucosa/immunology , Respiratory Mucosa/metabolism , Respiratory Mucosa/virology , Rhinovirus/immunology , Time Factors , Toll-Like Receptor 3/genetics , Toll-Like Receptor 3/metabolism
6.
Eur Respir J ; 39(2): 297-304, 2012 Feb.
Article in English | MEDLINE | ID: mdl-21719483

ABSTRACT

Respiratory virus infections play an important role in cystic fibrosis (CF) exacerbations, but underlying pathophysiological mechanisms are poorly understood. We aimed to assess whether an exaggerated inflammatory response of the airway epithelium on virus infection could explain the increased susceptibility of CF patients towards respiratory viruses. We used primary bronchial and nasal epithelial cells obtained from 24 healthy control subjects and 18 CF patients. IL-6, IL-8/CXCL8, IP-10/CXCL10, MCP-1/CCL2, RANTES/CCL5 and GRO-α/CXCL1 levels in supernatants and mRNA expression in cell lysates were measured before and after infection with rhinoviruses (RV-16 and RV-1B) and RSV. Cytotoxicity was assessed by lactate dehydrogenate assay and flow cytometry. All viruses induced strong cytokine release in both control and CF cells. The inflammatory response on virus infection was heterogeneous and depended on cell type and virus used, but was not increased in CF compared with control cells. On the contrary, there was a marked trend towards lower cytokine production associated with increased cell death in CF cells. An exaggerated inflammatory response to virus infection in bronchial epithelial cells does not explain the increased respiratory morbidity after virus infection in CF patients.


Subject(s)
Cystic Fibrosis , Nasal Mucosa , Picornaviridae Infections , Respiratory Mucosa , Rhinovirus/immunology , Bronchi/immunology , Bronchi/pathology , Bronchi/virology , Cell Line , Cystic Fibrosis/immunology , Cystic Fibrosis/pathology , Cystic Fibrosis/virology , Cytokines/genetics , Cytokines/immunology , Gene Expression/immunology , Humans , Immune System/immunology , Immune System/virology , Nasal Mucosa/immunology , Nasal Mucosa/pathology , Nasal Mucosa/virology , Picornaviridae Infections/immunology , Picornaviridae Infections/pathology , Picornaviridae Infections/virology , Primary Cell Culture , Respiratory Mucosa/immunology , Respiratory Mucosa/pathology , Respiratory Mucosa/virology , Rhinovirus/growth & development
8.
Eur Respir J ; 31(1): 36-42, 2008 Jan.
Article in English | MEDLINE | ID: mdl-17898016

ABSTRACT

The diagnosis of allergic bronchopulmonary aspergillosis (ABPA) in cystic fibrosis (CF) is a challenge. Thymus- and activation-regulated chemokine (TARC) has recently been reported to play a role in ABPA. The aim of this study was to compare the diagnostic value of TARC with that of known serological markers for diagnosis of ABPA in CF patients. The present study longitudinally followed 48 CF patients, of whom 12 had a diagnosis of ABPA according to Nelson's criteria, for 1-8 yrs with repeated measurements of serum total immunoglobulin (Ig)E, specific Aspergillus fumigatus IgE and IgG, specific IgE against recombinant A. fumigatus allergens (rAsp f) 1, 3, 4 and 6, and TARC. Median (interquartile range) TARC levels were 589 (465-673) pg x mL(-1) in ABPA patients and 232 (189-289) pg x mL(-1) in non-ABPA patients. Receiver operating characteristic curves revealed that TARC was superior to the other markers for diagnosis of ABPA. Diagnostic accuracy was greater for TARC (93%) than for total IgE (74%), or rAsp f 4 (75%) or f 6 (79%). The present study indicates that thymus- and activation-regulated chemokine may be useful in the diagnosis of allergic bronchopulmonary aspergillosis in cystic fibrosis patients. However, larger studies are needed before thymus- and activation-regulated chemokine can routinely be used in diagnostic algorithms.


Subject(s)
Aspergillosis, Allergic Bronchopulmonary/blood , Aspergillosis, Allergic Bronchopulmonary/complications , Cystic Fibrosis/blood , Cystic Fibrosis/complications , Adolescent , Allergens/chemistry , Aspergillus fumigatus/metabolism , Biomarkers/metabolism , Case-Control Studies , Chemokine CCL17/blood , Chemokines/metabolism , Child , Female , Humans , Immunoglobulin E/chemistry , Immunoglobulin G/chemistry , Male
9.
Pediatr Pulmonol ; 42(1): 41-50, 2007 Jan.
Article in English | MEDLINE | ID: mdl-17123315

ABSTRACT

Respiratory symptoms are common in infancy. Nevertheless, few prospective birth cohort studies have studied the epidemiology of respiratory symptoms in normal infants. The aim of this study was to prospectively obtain reliable data on incidence, severity, and determinants of common respiratory symptoms (including cough and wheeze) in normal infants and to determine factors associated with these symptoms. In a prospective population-based birth cohort, we assessed respiratory symptoms during the first year of life by weekly phone calls to the mothers. Poisson regression was used to examine the association between symptoms and various risk factors. In the first year of life, respiratory symptoms occurred in 181/195 infants (93%), more severe symptoms in 89 (46%). The average infant had respiratory symptoms for 4 weeks and 90% had symptoms for less than 12 weeks (range 0 to 23). Male sex, higher birth weight, maternal asthma, having older siblings and nursery care were associated with more, maternal hay fever with fewer respiratory symptoms. The association with prenatal maternal smoking decreased with time since birth. This study provides reliable data on the frequency of cough and wheeze during the first year of life in healthy infants; this may help in the interpretation of published hospital and community-based studies. The apparently reduced risk in children of mothers with hayfever but no asthma, and the decreasing effect of prenatal smoke exposure over time illustrate the complexity of respiratory pathology in the first year of life.


Subject(s)
Asthma/epidemiology , Cough/epidemiology , Respiratory Mechanics , Cohort Studies , Female , Humans , Incidence , Infant , Infant, Newborn , Male , Poisson Distribution , Prospective Studies , Reference Values , Remote Consultation , Respiratory Sounds , Risk Factors , Severity of Illness Index , Surveys and Questionnaires
10.
Ther Umsch ; 62(8): 539-42, 2005 Aug.
Article in German | MEDLINE | ID: mdl-16136818

ABSTRACT

The diagnosis of an acute asthmatic attack in a child is made on a clinical basis. The severity of the exacerbation can be assessed by physical examination and measurement of the transcutaneous oxygenation saturation. A blood gas analysis can be helpful in this assessment. A child with a severe asthma exacerbation should be promptly referred to an emergency department of a hospital. Oxygen should be given to keep the oxygen saturation above 92% and short-acting, selective beta-2 agonists should be administered. Beta-2 agonists can be delivered by intermittent nebulization, continuous nebulization or by metered dose inhaler (MDI) with a spacer They can also be given intravenously in patients who are unresponsive to escalating therapy. The early administration of systemic corticosteroids is essential for the management of acute asthma in children. When tolerated, systemic corticoseroids can be given orally but inhaled corticosteroids are not recommended. Oxygen delivery, beta-2 agonists and steroid therapy are the mainstay of emergency treatment. Hypovolemia should be corrected either intravenously or orally. Administration of multiple doses of ipratropium bromide has been shown to decrease the hospitalization rate in children and adolescents with severe asthma. Clinical response to initial treatment is the main criterion for hospital admission. Patients with failure to respond to treatment should be transferred to an intensive care unit. A critical aspect of management of the acute asthma attack in a child is the prevention of similar attacks in the future.


Subject(s)
Critical Care/methods , Emergencies , Emergency Treatment/methods , Risk Assessment/methods , Status Asthmaticus/diagnosis , Status Asthmaticus/therapy , Acute Disease , Adrenal Cortex Hormones/therapeutic use , Child , Child, Preschool , Emergency Medicine/methods , Germany , Humans , Infant , Infant, Newborn , Oxygen Inhalation Therapy/methods , Practice Guidelines as Topic , Practice Patterns, Physicians' , Risk Factors
12.
J Med Virol ; 65(1): 123-32, 2001 Sep.
Article in English | MEDLINE | ID: mdl-11505454

ABSTRACT

A multicentre study was undertaken to define novel assays with increased inter-assay concordance, sensitivity, specificity and predictive value for serological diagnosis of human herpesvirus type 8 (HHV-8) infection. A total of 562 sera from European and Ugandan human immunodeficiency virus (HIV)-infected or uninfected individuals with or without Kaposi's sarcoma (KS) and blood donors were examined under code by 18 different assays in seven European laboratories. Sera from KS patients and all non-KS sera found positive by at least 70%, 80%, or 90% of the assays were considered "true positive." The validity of the assays was then evaluated by univariate logistic regression analysis. Two immunofluorescence assays (IFA) for detection of antibodies against HHV-8 lytic (Rlyt) or latent (LLANA) antigens and two enzyme-linked-immunosorbent assays (ELISA) (M2, EK8.1) for detection of antibodies against HHV-8 structural proteins were found to be highly concordant, specific, and sensitive, with odds ratios that indicated a high predictive value. When used together, the two IFA (Rlyt-LLANA) showed the best combination of sensitivity (89.1%) and specificity (94.9%). The performance of these assays indicate that they may be used for the clinical management of individuals at risk of developing HHV-8 associated tumours such as allograft recipients.


Subject(s)
Antibodies, Viral/blood , Herpesvirus 8, Human/immunology , Sarcoma, Kaposi/diagnosis , AIDS-Related Opportunistic Infections/diagnosis , Enzyme-Linked Immunosorbent Assay/methods , Fluorescent Antibody Technique , HIV Infections/complications , Humans , Predictive Value of Tests , Sensitivity and Specificity
13.
J Med Virol ; 64(2): 157-66, 2001 Jun.
Article in English | MEDLINE | ID: mdl-11360248

ABSTRACT

The relationship between viral infection with Kaposi sarcoma-associated herpesvirus (KSHV) and the onset of Kaposi sarcoma (KS) in AIDS patients is incompletely understood. This study investigates the use of three serological assays to predict the development of KS in HIV-positive patients. Serially collected serum samples from 36 patients with KS and matched controls in the Swiss HIV Cohort Study (SHCS) were analyzed in a case control study. Three serologic assays to detect antibodies against KSHV (nuclear and membrane antigen immunofluorescence assay, N-IFA, M-IFA and ORF 65.2 ELISA) were used to determine the predictive value of KSHV-seropositivity. Serial samples from the cases were also analyzed to determine longitudinal patterns of seroreactivity and identify cases of seroconversion. Assay sensitivity for detection of KSHV antibodies was highest for M-IFA (83%), followed by N-IFA (74%) and 65.2 ELISA (52%). At the time of initial serum sampling (median 4.7 years before KS), only the N-IFA distinguished case and control sera (61% vs. 32%) and no assay was clearly predictive of subsequent onset of clinical KS. Moreover, an unexpectedly high rate of reversions to seronegativity were observed by N-IFA (27/33) as well as by 65.2 ELISA (11/26) in the longitudinal analysis. Analysis of the ORF65.2 ELISA index indicated that these reversions before the clinical onset of KS were associated with antibody levels that frequently hovered around the level of detectability. A marked increase in ORF 65.2 antibody titer occurred in a third of the patients at the time of KS diagnosis. Only two seroconversions were documented. KSHV infection within the SHCS is likely to have preceded HIV infection. KSHV infection alone is not highly predictive of KS development in this cohort of HIV-infected homosexual men as compared with matched controls. Three KSHV serologic assays, though sensitive at the time of clinical KS are inconsistently positive before the development of AIDS-related KS.


Subject(s)
AIDS-Related Opportunistic Infections/immunology , HIV Infections/immunology , HIV-1 , Herpesviridae Infections/epidemiology , Herpesvirus 8, Human/immunology , Sarcoma, Kaposi/immunology , AIDS-Related Opportunistic Infections/etiology , Case-Control Studies , Cohort Studies , HIV Infections/complications , HIV Infections/virology , Humans , Male , Nucleocapsid Proteins/immunology , Sarcoma, Kaposi/etiology , Seroepidemiologic Studies , Switzerland/epidemiology , Time Factors , Viral Envelope Proteins/immunology
15.
AIDS Res Hum Retroviruses ; 15(9): 803-10, 1999 Jun 10.
Article in English | MEDLINE | ID: mdl-10381168

ABSTRACT

The role of Bcl-2, Bax, and Bcl-x in the apoptosis of T lymphocytes in HIV-infected individuals was investigated. A strong correlation between Bcl-2 downregulation and spontaneous apoptosis has been reported by various groups in short-term cultures of CD8+ but not of CD4+ T lymphocytes. We describe a similar correlation in CD4+ T cells and provide an explanation why Bcl-2 downregulation in these cells has not been detected so far. In apoptotic cells not only Bcl-2, but also the CD4 surface receptors, are downregulated, preventing the detection of these cells in flow cytometric analysis. In contrast to Bcl-2, no correlation is detectable between Bax or Bcl-x expression and apoptosis. T lymphocytes of HIV-infected, but not of control, individuals display ex vivo a heterogeneous Bcl-2 expression pattern with a low and a high Bcl-2-expressing lymphocyte fraction. The proportion of low Bcl-2-expressing T cells correlates with a higher viral load in these individuals. Antiretroviral therapy significantly reduces the proportion of low Bcl-2-expressing lymphocytes, which is associated with a decrease in apoptosis. Bcl-2 downregulation and spontaneous apoptosis of T lymphocytes from HIV-infected individuals can be partially prevented by the exogeneous addition of IL-2, but not of IL-12, IL-4, or antibodies that prevent the CD95/CD95 ligand pathway of apoptosis.


Subject(s)
Anti-HIV Agents/therapeutic use , Apoptosis , CD4-Positive T-Lymphocytes/cytology , CD8-Positive T-Lymphocytes/cytology , Down-Regulation , HIV Infections/blood , HIV Protease Inhibitors/therapeutic use , Interleukin-2/metabolism , Proto-Oncogene Proteins c-bcl-2/biosynthesis , Proto-Oncogene Proteins/biosynthesis , Reverse Transcriptase Inhibitors/therapeutic use , Antibodies, Monoclonal/metabolism , CD4 Antigens/metabolism , CD4-Positive T-Lymphocytes/metabolism , CD8-Positive T-Lymphocytes/metabolism , Flow Cytometry , HIV Infections/drug therapy , Humans , Interleukin-12/metabolism , Interleukin-2/pharmacology , Interleukin-4/metabolism , Signal Transduction , bcl-2-Associated X Protein , bcl-X Protein , fas Receptor/metabolism
17.
N Engl J Med ; 339(19): 1358-63, 1998 Nov 05.
Article in English | MEDLINE | ID: mdl-9801396

ABSTRACT

BACKGROUND: Human herpesvirus 8 (HHV-8) has been detected in all forms of Kaposi's sarcoma, including transplantation-associated Kaposi's sarcoma. To investigate the possibility of transmission of HHV-8 through allografts, we measured the seroprevalence of HHV-8 before and after renal transplantation. METHODS: Using an enzyme-linked immunosorbent assay with the recombinant HHV-8 protein orf 65.2, we analyzed serum samples from 220 renal-transplant recipients for the presence of antibodies to HHV-8 on the day of transplantation and one year later. Positive results were confirmed by an indirect immunofluorescence assay that detects antibodies to latent antigen and by Western blotting. Follow-up lasted at least four years. RESULTS: The seroprevalence of HHV-8 in graft recipients increased from 6.4 percent on the day of transplantation to 17.7 percent one year after transplantation. Seroconversion occurred within the first year after transplantation in 25 patients, and Kaposi's sarcoma developed in 2 of them within 26 months after transplantation. Sequential serum samples were obtained from 10 of the patients with seroconversion, and in 8 of these patients, IgM antibodies to HHV-8 appeared within three months after transplantation. In the case of six patients who seroconverted, serum samples from the donors were available, and five (83 percent) tested positive for HHV-8. In a control group of eight patients who were seronegative at the time of transplantation and who received allografts from HHV-8-negative donors, none seroconverted within the year after transplantation. CONCLUSIONS: HHV-8 is transmitted through renal allografts and is a risk factor for transplantation-associated Kaposi's sarcoma.


Subject(s)
Antibodies, Viral/blood , Herpesvirus 8, Human/immunology , Kidney Transplantation/adverse effects , Sarcoma, Kaposi , Adolescent , Adult , Aged , Child , Female , Follow-Up Studies , Herpesviridae Infections/transmission , Humans , Male , Middle Aged , Risk Factors , Sarcoma, Kaposi/virology , Seroepidemiologic Studies , Tissue Donors
19.
J Clin Microbiol ; 36(6): 1784-6, 1998 Jun.
Article in English | MEDLINE | ID: mdl-9620422

ABSTRACT

The seroprevalence of human herpesvirus 8 (HHV-8) in the Swiss population was investigated. By enzyme-linked immunosorbent assay, sera reactive to the recombinant HHV-8 antigen orf 65.2 were found in 24% of human immunodeficiency virus (HIV)-positive patients without and in 92% of HIV-positive patients with Kaposi's sarcoma. Surprisingly, 20% of homosexual HIV-negative men, versus only 7% of heterosexual HIV-negative individuals and 5% of blood donors, had antibodies to HHV-8.


Subject(s)
Antibodies, Viral/blood , Herpesviridae Infections/epidemiology , Herpesvirus 8, Human/immunology , Homosexuality, Male , AIDS-Related Opportunistic Infections/epidemiology , Adult , Aged , Antigens, Viral/immunology , Cohort Studies , Enzyme-Linked Immunosorbent Assay , Female , HIV Seronegativity , Humans , Male , Middle Aged , Prevalence , Sarcoma, Kaposi/epidemiology , Sarcoma, Kaposi/immunology , Switzerland/epidemiology
SELECTION OF CITATIONS
SEARCH DETAIL
...